Fairmount Funds Management LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Fairmount Funds Management LLC reported 15 stock positions worth $917.4 million. Its top holding was Axsome Therapeutics (AXSM) at 20.5% of the portfolio, followed by Nuvalent Class A (NUVL, 15.8%) and Apogee Therapeutics (APGE, 14.8%). Compared with Q4 2023, it opened 2 new positions, sold out of 3, added to 5 and reduced 1. The biggest buy was Dianthus Therapeutics (DNTH, shares +43%) and the biggest sale an exit from Immunogen (IMGN).
- Most Recent 13F
- Q2 2026
- Location
- WEST CONSHOHOCKEN, PA
- CIK
- 0001802528
- Portfolio Value
- $917.4M (Q1 2024)
- SEC Filing
- 0001104659-24-061870 ↗ filed May 15, 2024
Holdings Value
Holdings 15 stocks · $917.4M
| AXSM Axsome Therapeutics Inc. | 20.53% | 2,360,077 | $188.3M | No change |
| NUVL Nuvalent Inc. Class A | 15.75% | 1,924,626 | $144.5M | No change |
| APGE Apogee Therapeutics Inc. | 14.84% | 2,048,647 | $136.1M | Reduce -30.4% |
| DNTH Dianthus Therapeutics Inc. | 9.03% | 2,762,837 | $82.9M | Add +43.3% |
| KNSA Kiniksa Pharmaceuticals Ltd. | 6.89% | 3,204,841 | $63.2M | Add +11.2% |
| ELVN Enliven Therapeutics Inc. | 6.14% | 3,202,798 | $56.3M | Add +50.3% |
| ATXS Astria Therapeutics Inc. | 5.45% | 3,554,129 | $50.0M | No change |
| VRDN Viridian Therapeutics Inc. | 3.52% | 1,845,813 | $32.3M | Add +34.8% |
| MRUS Merus NV | 3.52% | 717,254 | $32.3M | No change |
| COGT Cogent Biosciences Inc. | 3.46% | 4,725,641 | $31.8M | Add +32.8% |
| PTGX Protagonist Therapeutics Inc. | 2.94% | 931,890 | $27.0M | New |
| TYRA Tyra Biosciences Inc. | 2.49% | 1,393,329 | $22.9M | No change |
| GERN Geron Corp. | 2.40% | 6,666,667 | $22.0M | New |
| SYRE Spyre Therapeutics Inc. | 1.56% | 378,421 | $14.4M | No change |
| TERN Terns Pharmaceuticals Inc. | 1.46% | 2,040,000 | $13.4M | No change |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
| DNTH Dianthus Therapeutics Inc. | Add +43.3% | 9.03% | +6.92 |
| ELVN Enliven Therapeutics Inc. | Add +50.3% | 6.14% | +3.02 |
| PTGX Protagonist Therapeutics Inc. | New | 2.94% | +2.94 |
| GERN Geron Corp. | New | 2.40% | +2.40 |
| KNSA Kiniksa Pharmaceuticals Ltd. | Add +11.2% | 6.89% | +1.55 |
| COGT Cogent Biosciences Inc. | Add +32.8% | 3.46% | +1.25 |
| VRDN Viridian Therapeutics Inc. | Add +34.8% | 3.52% | +0.37 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.5B | ORKA, DNTH, DMRA, COGT, JBIO |
| Q1 2026 | 12 | $1.4B | DMRA, DNTH, COGT, SYRE, ORKA |
| Q4 2025 | 13 | $1.3B | COGT, APGE, SYRE, VRDN, ORKA |
| Q3 2025 | 17 | $1.1B | DNTH, COGT, AXSM, APGE, ELVN |
| Q2 2025 | 17 | $771.9M | APGE, AXSM, ELVN, SRRK, SYRE |
| Q1 2025 | 15 | $644.6M | AXSM, APGE, SYRE, ELVN, NUVL |
| Q4 2024 | 17 | $1.0B | AXSM, NUVL, SYRE, APGE, SRRK |
| Q3 2024 | 15 | $1.2B | AXSM, NUVL, APGE, SYRE, ELVN |
| Q2 2024 | 13 | $885.1M | AXSM, NUVL, SYRE, APGE, ELVN |
| Q1 2024 | 15 | $917.4M | AXSM, NUVL, APGE, DNTH, KNSA |